NextCell presents their latest phase II clinical data at ISCT 2021
NextCell Pharma AB (“NextCell”) announces today that they will present their findings from their Phase I/II study entitled “Wharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes” (NCT 03406585) at the International Society of Cell and Gene Therapy virtual conference 2021 (May 26th-28th).
NextCell’s CSO, Dr. Lindsay Davies will attend the meeting and present a poster entitled “Protrans Wharton’s Jelly Mesenchymal Stromal Cells Preserve Beta Cell Function in Newly Diagnosed Type I Diabetes Patients – A Randomised, Double-Blinded, Placebo Controlled Phase II Trial” (Poster #111).
NextCell, in collaboration with the Principal Investigator for the trial, Prof. Per-Ola Carlsson of Uppsala University Hospital, outline their study findings highlighting the therapeutic effect of a single infusion of ProTrans in maintaining beta cell function in early diagnosed, adult type I diabetics.
Dr Mathias Svahn, CEO of NextCell commented, “We are extremely happy to share the data from our latest Phase I/II trial in type I diabetic patients using our mesenchymal stromal cell drug candidate, ProTrans. It is an honour for us to be selected to share these data at the ISCT meeting this year.”
NextCell are actively involved in the ISCT. Dr Lindsay Davies is a member of the Commercialisation Committee, Process and Product Development Committee and the Particulate Working Group. Dr Davies is also a mentor for Early Stage Professionals in Cell Therapy for ISCT Europe. Dr Mathias Svahn is a member of the ISCT’s Business Models and Investment Committee.
Stay up to date with the latest development in NextCell Pharma
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Sofia Fredrikson, CFO
Phone: 08-735 5595
E-mail: info@nextcellpharma.com
Website:
www.nextcellpharma.com, www.cellaviva.se
www.cellaviva.dk
About NextCell Pharma AB
NextCell is a Phase II cell therapy company with the lead candidate ProTrans™, for the treatment of type-1 diabetes. Focus is to take ProTrans™ to market approval via a phase III study. Furthermore, NextCell operates Cellaviva, Scandinavia's largest stem cell bank for family-saving of stem cells from umbilical cord blood and umbilical cord tissue with permission from IVO.
FNCA Sweden AB is assigned as Certified Adviser, 08-528 00 399, info@fnca.se.